Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets.
The role of CD19(+) CD5(+) and CD19(+) CD5(-) B cell subpopulations in the antibody response to pneumococcal capsular polysaccharides (caps-PSs) is controversial. In the present study, we evaluated the role of human CD19(+) CD5(+) and CD19(+) CD5(-) cell populations in the serotype-specific antibody response to caps-PS. After vaccination of 5 healthy human adults with Pneumovax (23-valent pneumococcal polysaccharide vaccine [PPV23]), IgG anti-caps-PS serotype 4 antibody-producing cells resided mainly in the CD19(+) CD5(-) B cell subset, as assessed by enzyme-linked immunosorbent spot (ELISpot) analysis. Moreover, in a humanized SCID mouse model, CD19(+) CD5(-) B cells were more effective than CD19(+) CD5(+) cells in producing IgG anti-cap-PS antibodies. Finally, an association was found between the level of IgG anti-caps-PS antibodies and the number of CD19(+) CD5(-) B cells in 33 humans vaccinated with PPV23. Taken together, our data suggest that CD5 defines a functionally distinct population of B cells in humans in the anti-caps-PS immune response.
Experimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Leen
L
Moens
Experimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium Life Sciences, Thomas More Kempen, Geel, Belgium.
Bert
B
Verbinnen
Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, Faculty of Medicine, KU Leuven, Leuven, Belgium.
Kris
K
Covens
Experimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Greet
G
Wuyts
Immunobiology Section, Institute of Child Health, University College London, London, United Kingdom.
Marina
M
Johnson
Immunobiology Section, Institute of Child Health, University College London, London, United Kingdom.
Lucy
L
Roalfe
Immunobiology Section, Institute of Child Health, University College London, London, United Kingdom.
David
D
Goldblatt
Pediatrics, University Hospitals, Leuven, Belgium.
Isabelle
I
Meyts
Experimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium Xavier.Bossuyt@uzleuven.be.
Xavier
X
Bossuyt
D000293:Adolescent; D000328:Adult; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood*; D000917:Antibody Formation; D018941:Antigens, CD19 / Q000032:analysis; D016175:B-Lymphocyte Subsets / Q000737:chemistry / Q000276:immunology*; D018956:CD5 Antigens / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D016513:Mice, SCID; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000276:immunology*; D055815:Young Adult
D000907:Antibodies, Bacterial; D018941:Antigens, CD19; D018956:CD5 Antigens; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines